Holding(s) in Company

Arix Bioscience

04/04/2018 09:01

RNS Number : 7602J

Arix Bioscience Plc

04 April 2018

 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
Arix Bioscience Plc
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii:
3. Details of person subject to the notification obligationiv
Name
Ruffer LLP
City and country of registered office (if applicable)
London, United Kingdom
4. Full name of shareholder(s)(if different from 3.)v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reachedvi:
29 March 2018
6. Date on which issuer notified (DD/MM/YYYY):
03 April 2018
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% ofvoting rights throughfinancial instruments
 (total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights of issuervii
Resulting situation on the date on which threshold was crossed or reached
5%
0%
5%
134,764,018
Position of previous notification (if
applicable)
N/A
N/A
N/A


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii
A: Voting rights attached to shares
Class/type of
 shares
ISIN code (if possible)
Number of voting rightsix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
GB00BD045071
6,921,088
0
5%
0%
SUBTOTAL 8. A
6,921,088
5%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
N/A
N/A
N/A
N/A
N/A
SUBTOTAL 8. B 1
N/A
N/A
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expiration
 datex
Exercise/
 Conversion Periodxi
Physical or cash
settlementxii
Number of voting rights
% of voting rights
N/A
N/A
N/A
N/A
N/A
N/A
SUBTOTAL 8.B.2
N/A
N/A


 

9. Information in relation to the person subject to the notification obligation(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii
X
Fullchain of controlled undertakings through which the voting rights and/or the
 financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv(please add additional rows as necessary)
Namexv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
N/A
N/A
N/A
N/A
10.In case of proxy voting, please identify:
Name of the proxy holder
N/A
The number and % of voting rights held
N/A
The date until which the voting rights will be held
N/A
11. Additional informationxvi
Ruffer LLP now controls the voting rights over 6,921,088 shares (5% of the voting rights) of Arix Bioscience Plc which are held by the discretionary clients of Ruffer LLP and its subsidiaries (the voting of which is all controlled by Ruffer LLP).
This change from less than 5% to 5% is due to the purchase by Ruffer LLP of 432,200 shares on 29 March 2018.


 

Place of completion
Ruffer LLP
Date of completion
03/04/18

 

 

This information is provided by RNS

The company news service from the London Stock Exchange

 

END

 

 

HOLIIMRTMBTMMJP